Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05329142
Other study ID # GN21AE239
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 19, 2022
Est. completion date August 19, 2023

Study information

Verified date September 2022
Source NHS Greater Glasgow and Clyde
Contact Lisa C Dunlop, MBChB, BSc FRCEM
Phone 0141 452 2930/1
Email lisa.dunlop2@nhs.scot
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

There is a drug-related death crisis in Scotland. This study aims to collaborate with Public Health Scotland in order to assess the feasibility of introducing a surveillance system to the Emergency Department to highlight illicit drug-related attendances. This will utilise both clinical data and toxiclogical analysis of anonymised samples. The data will inform of prevalence, trend data and utcome of ED patients attending with acute illict drug toxicity.


Description:

The purpose of this research is to establish the introduction of a robust toxicology surveillance system in the Emergency Department (ED) in order to inform public health interests. The study will explore the feasibility of reporting characteristics and causative agents of patients attending hospital as an emergency due illicit substance use. The term illicit substance used during this study encompasses any substance which is not prescribed to the individual and is a controlled drug as per the Misuse of Drugs act 1971 and Misuse of Drugs Regulations 2001. The study will look at standard care clinical data from all individuals attending the Emergency Department due to acute illicit drug toxicity. Surplus blood samples will be anonymised and analysed for toxicological profiling. The study will allow identification of emerging drug trends and will be shared contemporaneously with Public Health Scotland and inform the Scottish Government of current incidences to inform public health measures to tackle the drugs death crisis.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date August 19, 2023
Est. primary completion date August 19, 2023
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: - Age >16 - Patient attending QEUH ED directly relating to acute illicit drug use - Patients with reported acute illicit drug use toxicity who are unwell before they are seen in the Emergency Department but appear well in the ED should also be included Exclusion Criteria: - Condition more likely due to cause other than acute illicit drug use - Condition due to withdrawal of drugs / alcohol - Condition primarily related to alcohol use and no evidence of acute illicit drug use - Attendance is due to complication of previous drug use - i.e., BBV / infected injection site (without acute drug toxicity)

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Surplus sample toxicology analysis
Anonymised surplus blood sample will be analysed for drugs and their metabolites by way of Mass Spectrometry and LGC Group, Cambridge.

Locations

Country Name City State
United Kingdom Queen Elizabeth University Hospital, NHS GGC Glasgow

Sponsors (2)

Lead Sponsor Collaborator
NHS Greater Glasgow and Clyde Public Health Scotland

Country where clinical trial is conducted

United Kingdom, 

References & Publications (15)

Adams AJ, Banister SD, Irizarry L, Trecki J, Schwartz M, Gerona R. "Zombie" Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York. N Engl J Med. 2017 Jan 19;376(3):235-242. doi: 10.1056/NEJMoa1610300. Epub 2016 Dec 14. — View Citation

Deaths mentioning a new psychoactive substance by broad age-group, England and Wales, 2011 to 2015 registrations. 18 January 2017. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/adhocs/06556deathsmentioninganewpsychoactivesubstancebybroadagegroupenglandandwales2011to2015registrations. Accessed 19/12/2018

Di Rico R, Nambiar D, Stoové M, Dietze P. Drug overdose in the ED: a record linkage study examining emergency department ICD-10 coding practices in a cohort of people who inject drugs. BMC Health Serv Res. 2018 Dec 5;18(1):945. doi: 10.1186/s12913-018-3756-8. — View Citation

EMCDDA. Drug-related deaths and mortality in Europe. Update from EMCDDA expert network July 2019. Available from https://www.emcdda.europa.eu. Accessed 09/02/2020

EMCDDA. European Drug Report, trends and Developments 2021. Available from https://www.emcdda.europa.eu/system/files/publications/13838/TDAT21001ENN.pdf accessed 14/02/2022

European Monitoring Centre for Drugs and Drug Addiction (2021), European Drug Report 2021: Trends and Developments, Publications Office of the European Union, Luxembourg.

European Monitoring Centre for Drugs and Drug Addiction. (2016) Health responses to new psychoactive substances. Available from http://www.emcdda.europa.eu/system/files/publications/2812/TD0216555ENN.pdf. Accessed 15/02/2022

Hikin L, Smith PR, Ringland E, Hudson S, Morley SR. Multiple fatalities in the North of England associated with synthetic fentanyl analogue exposure: Detection and quantitation a case series from early 2017. Forensic Sci Int. 2018 Jan;282:179-183. doi: 10.1016/j.forsciint.2017.11.036. Epub 2017 Nov 29. — View Citation

National Records of Scotland. Drug-related deaths in Scotland in 2020, published 30/07/21. Available from https://www.nrscotland.gov.uk. Accessed 14/02/2022.

Office for National Statistics. Drug misuse in England and Wales: year ending March 2020 09/12/2020. Accessed 16/02/2022

Public Health Scotland, Drug-related Hospital Statistics, Scotland 2019 - 2020. Published 15/06/2021. Available from https://publichealthscotland.scot/. Accessed 14/02/2022

Scottish Government. Evidence-Based Strategies for Preventing Drug-Related Deaths in Scotland, Our Emergency Response. January 2020. Available from https://www.gov.scot/. Accessed 10/02/2021

Seywright A, Torrance HJ, Wylie FM, McKeown DA, Lowe DJ, Stevenson R. Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA. Clin Toxicol (Phila). 2016 Sep;54(8):632-7. doi: 10.1080/15563650.2016.1186805. Epub 2016 May 23. — View Citation

The Misuse if Drugs Regulations 2001, Dangerous Drugs. Available from legislation.giv.uk. Accessed 25/02/2022.

UK Public General Acts. Misuse of Drugs Act 1972 Schedule 2. Available from legislation.gov.uk. Accessed 25/02/2022

* Note: There are 15 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of full data sets and toxicology analysis for all patient attending the ED due to acute illicit drug toxicity Objective:
Assess the feasibility of prospective surveillance of Emergency Department presentations relating to acute illicit drug toxicity
Outcome measure:
Proportion of full data sets and toxicology analysis for all patient attending the ED due to acute illicit drug toxicity
1 year
Secondary Clinical phenotyping of patients attending due to acute illicit drug toxicity compared to reported / presumed drug taken Objective:
Describe the clinical characteristics and reported / presumed toxicological profile of drug related presentations to the Emergency Department
Outcome measure:
Clinical phenotyping of patients attending due to acute illicit drug toxicity compared to reported / presumed drug taken
1 year
Secondary Proportion of patients who fit stage 2 criteria with biological sample mass spectrometry toxicology analysis Objective:
Establish the feasibility of ED presentation toxicological surveillance by anonymised surplus sample mass spect analysis
Outcome Measure:
Proportion of patients who fit stage 2 criteria with biological sample mass spectrometry toxicology analysis
1 year
Secondary Production of frequency and trend data to deliver to Public Health Scotland Objective:
Describe the frequency and trends of drug related presentations to the ED, both clinically and by biological sample analysis
Outcome measure:
Production of frequency and trend data to deliver to Public Health Scotland
1 year
Secondary Proportion of illicit drug reported to have been taken and proportion of clinician presumed drug taken accurately matching toxicology analysis Objective:
Assess the accuracy of reported / clinician presumptive toxidrome diagnosis compared to biological sample analysis
Outcome Measure:
Proportion of illicit drug reported to have been taken and proportion of clinician presumed drug taken accurately matching toxicology analysis
1 year
Secondary Production of automated pre-defined data capture, recording and auditing for the routine processing of drug related ED presentations that includes toxicological information Objective:
Develop a framework to standardise data capture, recording and auditing for the routine processing of drug related ED presentations that includes toxicological information
Outcome measure:
Production of automated pre-defined data capture, recording and auditing for the routine processing of drug related ED presentations that includes toxicological information
1 year
Secondary Share learning and data with Scottish Government, PHS and other NHS boards to inform national scale up Objective:
Identify and compare options for national scale up - including the use of existing hospital toxicology facilities and additional services
Outcome measure:
Share learning and data with Scottish Government, PHS and other NHS boards to inform national scale up
1 year
See also
  Status Clinical Trial Phase
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Completed NCT02224508 - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks N/A
Completed NCT02375516 - Preventing Drug Abuse Among Hispanic Adolescents N/A
Withdrawn NCT01275391 - cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use Phase 1/Phase 2
Completed NCT01442753 - Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth N/A
Completed NCT00907309 - Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use Phase 1/Phase 2
Completed NCT02228044 - Alcohol, Suicide and HIV Prevention for Teens in Mental Health Treatment N/A
Withdrawn NCT01427465 - Brief Integrative Alcohol Interventions for Adolescents N/A
Completed NCT00350909 - Brief Intervention for Drug Abusing Adolescents Phase 2
Completed NCT00148031 - Improving Hepatitis C Treatment in Injection Drug Users Phase 4
Completed NCT00383838 - Self-Selected Brief Alcohol Intervention for Adolescents N/A
Completed NCT00722644 - Cognitive Behavioral Stress Management for HIV+ Drug Abusers Phase 1
Completed NCT00451854 - Student Athlete Testing Using Random Notification N/A
Completed NCT01036711 - Effects of Nicotine on Cognitive Task Performance and Brain Activity as Measured by fMRI
Terminated NCT02741076 - Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain Phase 4
Completed NCT01035723 - Effect of Functional Genetic Polymorphisms on Brain Morphology and Function
Completed NCT06044363 - Satir Model for Self-esteem, Mental Health, and Family Function Among Individuals With Substance Use Disorders N/A
Recruiting NCT05037487 - Evaluation of Smoked THC and CBD in Men and Women Phase 1
Recruiting NCT04725266 - A Family-based Intervention for Drug-abusing Adults in Hong Kong N/A
Completed NCT03678051 - CBT4CBT for Women in Residential Treatment for Substance Use Disorders N/A